Search
Biogen Inc
BIIBAdd to Watchlist
202.190USD
+1.570+0.78%
Close 07-24 16:00（ET）Quotes delayed by 15 min
29.84BMarket Cap
21.63P/E TTM
Revenue Breakdown
Currency: USDUpdated: Mon, Apr 6
Currency: USDUpdated: Mon, Apr 6
FY2025
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
By BusinessUSD
Name
Revenue
Proportion
Spinal Muscular Atrophy-SPINRAZA
2.15B
21.78%
MS product revenues-TYSABRI
1.67B
16.84%
MS product revenues-Fumarate
1.43B
14.42%
MS product revenues-Interferon
945.60M
9.56%
Biosimilar product revenues-BENEPALI
453.20M
4.58%
Other
3.25B
32.82%
By RegionUSD
Name
Revenue
Proportion
United States
3.73B
37.67%
Rest of world
3.57B
36.11%
United states-Revenues from anti-CD20 therapeutic
1.86B
18.81%
Rest of World-Other revenues
732.90M
7.41%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Spinal Muscular Atrophy-SPINRAZA
2.15B
21.78%
MS product revenues-TYSABRI
1.67B
16.84%
MS product revenues-Fumarate
1.43B
14.42%
MS product revenues-Interferon
945.60M
9.56%
Biosimilar product revenues-BENEPALI
453.20M
4.58%
Other
3.25B
32.82%